1385results about How to "Toxic reduction" patented technology

In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of a pharmaceutically active agent, wherein the agent is associated with a polymeric biocompatible material.

Desalination methods that include carbonate compound precipitation are provided. In certain embodiments, feed water is subjected to carbonate compound precipitation conditions prior to desalination. In certain embodiments, desalination waste brine is subjected to carbonate compound precipitation conditions. In yet other embodiments, both feed water and waste brine are subjected to carbonate compound precipitation conditions. Aspects of embodiments of the invention include carbone dioxide sequestration. Embodiments of the invention further employ a precipitate product of the carbonate compound precipitation conditions as a building material, e.g., a cement. Also provided are systems configured for use in methods of the invention.

The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

Ethanol was produced using biocatalysts that are able to ferment sugars derived from treated biomass. Sugars were obtained by pretreating biomass under conditions of high solids and low ammonia concentration, followed by saccharification.

The invention is directed to a polypeptide comprising a human IL-2 mutein numbered in accordance with wild-type IL-2 wherein said human IL-2 is substituted at at least one of positions 20, 88 or 126, whereby said mutein preferentially activates T cells over NK cells. D20H and I, N88G, I, and R, in particular have a relative T cell-differential activity much greater than native IL-2, with predicted associated reduced in vivo toxicity. The invention also includes polynucleotides coding for the muteins of the invention, vectors containing the polynucleotides, transformed host cells, pharmaceutical compositions comprising the muteins, and therapeutic methods of treatment.

The invention features compositions, methods, and kits for the treatment of metabolic disorders such as diabetes and obesity.

The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering a non-steroidal immunophilin-dependent immunosuppressant (NsIDI) and a Group A enhancer (e.g., antifungal agent, antigout agent, anti-infective agent, antiprotozoal agent, antiviral agent, humectant, sunscreen, vitamin D compound, microtubuline inhibitor, or zinc salt) or analog or metabolite thereof to the patient. The invention also features a pharmaceutical composition containing an NsIDI and Group A enhancer or analog or metabolite thereof for the treatment or prevention of an immunoinflammatory disorder.

Biologically active agents covalently linked to a polymer. The polymer is preferably a biodegradable polymer are provided. The biologically active agent is preferably a protein, such as an extracellular soluble protein, e.g., an extracellular enzyme. The enzyme can be an apyrase, e.g., NTPDase. Conjugates of the invention can be used as therapeutics in subjects. For example, a conjugate comprising an apyrase can be used for treating and preventing thrombosis, atherosclerotic plaque complications and vascular disorders.

A self-healing material comprises a matrix embedded with micro-pockets of a healing-agent releasable by a crack in the matrix. The healing-agent is able to bond to the matrix to repair the crack. The healing-agent is contained in microcapsules. A corresponding catalyst for the healing-agent is embedded in the matrix and contained in a plurality of microcapsules as an emulsion. The emulsion comprises an oil, a perfluorated solvent, a hydrophobic ionic liquid, or mixtures thereof. A method of manufacturing the self-healing material comprises the steps of identifying an operational temperature range of the material, providing at least one substance as the healing-agent, which substance remaining substantially in a liquid state within the operational temperature range, identifying an operational evaporation rate of the healing-agent and providing the substance with a curing time according to the evaporation rate.

The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient an antihistamine, either alone or in combination with one or more additional agents. The invention also features a pharmaceutical composition containing an antihistamine in combination with one or more additional agents.

A method for forming a thin film photovoltaic device includes providing a transparent substrate comprising a surface region and forming a first electrode layer overlying the surface region. The method further includes forming a thin layer of copper gallium material overlying the first electrode layer to act as an intermediary adhesive layer to facilitate attachment to the first electrode layer. Additionally, the method includes forming a copper layer overlying the thin layer and forming an indium layer overlying the copper layer to form a multilayered structure and subjecting the multilayered structure to thermal treatment process with sulfur bearing species to form a copper indium disulfide alloy material. The copper indium disulfide alloy material comprises a copper:indium atomic ratio of about 1.2:1 to about 3.0:1 overlying a copper gallium disulfide material converted from the thin layer. Furthermore, the method includes forming a window layer overlying the copper indium disulfide alloy material.

The invention relates to conformationally constrained mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.

One kind of short range nitrifying-anaerobic aminoxidizing sequencing batch type denitrifying biomembrane mode and plant is disclosed. The limited aerating mode with real-time control of the sewage temperature inside the reactor and high frequency alternation between aeration and anaeration can inhibit the growth of nitrite oxidizing bacteria and denitrifying bacteria so that the aminoxidizing bacteria and the anaerobic aminoxidizing bacteria become the dominant bacteria in the nitrifying and denitrifying stages. In the nitrifying stage, nitrification is stopped in the nitrite step; and in the denitrifying stage, ammonia nitrogen acts as the direct electron donor to reduce nitrite. The plant is provided with fixed spherical composite stuffing with spherical shell of polypropylene and filled inside biological composite material. Sectional discrete water feeding mode is adopted to feed the sewage to be treated in four stages into the reactor.

A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.

The invention features dosing regimens for the administration of combination therapies, wherein one of the drugs of the combination is formulated for sustained release, or administered repeatedly, and compositions related thereto.

A method of preparing an antioxidant polymer includes forming or obtaining a first polymer having reactive pendant groups, where the first polymer does not include cyclic anhydride repeat units, and derivatizing the first polymer with an antioxidant. Another method of preparing an antioxidant polymer includes forming or obtaining a first polymer having reactive pendant groups and derivatizing the first polymer with an antioxidant, where the antioxidant is attached to the first polymer by an acetal, amide, amine, carbamate, carbonate, ester, ether or thioether linkage or by a carbon-carbon bond. The invention is also directed to polymers that are generally prepared by these methods, compositions that include such polymers and methods of using such polymers.